The immunosuppressive effect of Siglec15 in TME is the most obvious in BLCA, which suggests that BLCA may be a suitable candidate cancer type for anti-Siglec15 immunotherapy. This evidence concerns the gene SIGLEC15 and bladder transitional cell carcinoma.